CN114392248B - Preparation method of anthocyanin-carrying nanoparticles - Google Patents
Preparation method of anthocyanin-carrying nanoparticles Download PDFInfo
- Publication number
- CN114392248B CN114392248B CN202210025792.2A CN202210025792A CN114392248B CN 114392248 B CN114392248 B CN 114392248B CN 202210025792 A CN202210025792 A CN 202210025792A CN 114392248 B CN114392248 B CN 114392248B
- Authority
- CN
- China
- Prior art keywords
- anthocyanin
- nanoparticles
- carrying
- polyethylene glycol
- hpda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000004410 anthocyanin Substances 0.000 claims abstract description 78
- 235000010208 anthocyanin Nutrition 0.000 claims abstract description 78
- 229930002877 anthocyanin Natural products 0.000 claims abstract description 78
- 150000004636 anthocyanins Chemical class 0.000 claims abstract description 77
- 229920001690 polydopamine Polymers 0.000 claims abstract description 65
- 229920001661 Chitosan Polymers 0.000 claims abstract description 44
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 30
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 30
- 238000001179 sorption measurement Methods 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 6
- 239000000969 carrier Substances 0.000 claims abstract description 5
- 235000008708 Morus alba Nutrition 0.000 claims description 59
- 240000000249 Morus alba Species 0.000 claims description 59
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 16
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 13
- 229910021641 deionized water Inorganic materials 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 7
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims description 7
- 229960001149 dopamine hydrochloride Drugs 0.000 claims description 7
- 229920001992 poloxamer 407 Polymers 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 238000005530 etching Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- YOVXRIACERVBAG-UHFFFAOYSA-N 6-hydroxy-2-oxo-6-phenylhexa-3,5-dienoic acid Chemical compound OC(=O)C(=O)C=CC=C(O)C1=CC=CC=C1 YOVXRIACERVBAG-UHFFFAOYSA-N 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 4
- 230000002292 Radical scavenging effect Effects 0.000 abstract description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002086 nanomaterial Substances 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- -1 anthocyanin compounds Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 238000002336 sorption--desorption measurement Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of nano materials, and discloses a preparation method of anthocyanin-carrying nanoparticles, wherein the prepared nanoparticles comprise the following components in percentage by mass: 8-11: 6-10 mesoporous polydopamine nanoparticles, anthocyanin and polyethylene glycol modified chitosan, wherein the mesoporous polydopamine nanoparticles are used as carriers, the anthocyanin is adsorbed by physical and chemical adsorption, and the polyethylene glycol modified chitosan is wrapped on the outermost layer. The nanoparticle can maintain high DPPH, hydroxyl radical scavenging activity and anticancer activity of anthocyanin, and increase stability of anthocyanin.
Description
Description of the division
The invention discloses a divisional application of a year 2020, a month 12 and a day 31, an application number 202011631110X and a name of the invention being 'anthocyanin-carrying nano-particles' and a preparation method thereof.
Technical Field
The invention relates to the technical field of nano materials, in particular to a preparation method of anthocyanin-carrying nanoparticles.
Background
Mulberry is a medicinal and edible traditional Chinese medicine, fruits of the mulberry are rich in anthocyanin compounds, mulberry anthocyanin is a water-soluble natural pigment widely existing in flowers, fruits and leaves of plants, belongs to flavonoid polyphenol compounds, has strong antioxidant capacity, and can promote human health. The food can not only maintain beauty and keep young, protect liver, resist tumor and oxidation, prevent arteriosclerosis, etc., but also has the effect of remarkably improving the immunity of human bodies. Anthocyanin can also improve ethanol-induced neurotoxicity in brain development process, prevent cerebral arterial occlusion, reperfusion injury, promote rhodopsin regeneration, etc. However, the stability of the mulberry anthocyanin can be affected by internal and external factors such as unstable temperature, concentration, illumination, pH, enzyme, oxygen, ascorbic acid, sugar and degradation products thereof, metal ions, self-structure and the like. There is a need to prepare a suitable drug delivery system to solve the above problems, to improve the water solubility and stability of mulberry anthocyanin, to prevent the drug from being hydrolyzed, oxidized and inactivated after entering the organism, and to extend the in vivo release time.
Polydopamine (PDA) is a main component of natural biological pigment-melanin, can be obtained through oxidation self-polymerization reaction of dopamine, has good stability, biodegradability, biocompatibility and photo-thermal conversion characteristics, and is an ideal carrier material. The polydopamine surface has a large number of catechol and amino functional groups, has strong adhesion, and can be coated on the surfaces of various materials. Polydopamine is also pH sensitive and depolymerizes in the slightly acidic environment of tumors. The hollow mesoporous polydopamine nanoparticle (HPDA) can be prepared by a hard template method, and has high specific surface area, a nano pore structure and an internal hollow structure, high-efficiency drug loading and good photo-thermal conversion performance. Chitosan is a cationic polymer composed of glucosamine, has good biocompatibility, low toxicity and biodegradability, has intestinal mucosa adhesion property, and is favorable for oral absorption of medicines as a medicine auxiliary material. The polyethylene glycol modification is carried out on the chitosan, so that the adsorption effect of plasma protein on the chitosan coated mesoporous polydopamine nanoparticles can be reduced, the ingestion of macrophages on the chitosan coated mesoporous polydopamine nanoparticles is reduced, the process that the drug-carrying nanoparticles are removed from the plasma is delayed, and the passive targeting function of the chitosan mesoporous polydopamine nanoparticles is further improved through the enhanced permeation and retention effect.
Disclosure of Invention
The invention aims to: aiming at the problems existing in the prior art, the invention provides a preparation method of anthocyanin-carrying nanoparticles, which can maintain higher DPPH, hydroxyl radical scavenging activity and anticancer activity of anthocyanin and increase the thermal stability of anthocyanin.
The technical scheme is as follows: the invention provides anthocyanin-carrying nanoparticles, which are characterized by comprising the following components in percentage by mass of 52-59: 8-11: 6-10 mesoporous polydopamine nanoparticles, anthocyanin and polyethylene glycol modified chitosan, wherein the mesoporous polydopamine nanoparticles are used as carriers, the anthocyanin is adsorbed by physical and chemical adsorption, and the polyethylene glycol modified chitosan is wrapped on the outermost layer.
Preferably, the anthocyanin is mulberry anthocyanin.
The invention also provides a preparation method of the anthocyanin-carrying nanoparticle, which comprises the following steps: (1) Adding dopamine hydrochloride and Pluronic F127 into an ethanol aqueous solution, stirring at room temperature uniformly, adding silicon dioxide particles, then dropwise adding TMB to form white emulsion, adding an ammonia aqueous solution, stirring, centrifuging, ultrasonically washing the precipitate with ethanol and water for a plurality of times, adding the precipitate into a hydrofluoric acid aqueous solution for etching, centrifuging to obtain hollow mesoporous polydopamine nanoparticles, and marking as HPDA; the weight-volume ratio of the dopamine hydrochloride to the Pluronic F127 to the silicon dioxide to the TMB to the ammonia solution is 0.2-0.5 g: 0.8-1.2 g: 0.8-1.0 mL: 4.0-5.0 mL; (2) Adding the hollow mesoporous polydopamine nanoparticle obtained in the step (1) and anthocyanin powder into deionized water, stirring at room temperature for reaction, centrifuging, and washing with deionized water for several times to obtain anthocyanin-carrying nanoparticle, wherein the anthocyanin-carrying nanoparticle is marked as HPDA@MAS; the mass ratio of the hollow mesoporous polydopamine nanoparticle to the anthocyanin powder is 7-11: 1, a step of; (3) Weighing a certain amount of chitosan and polyethylene glycol, dissolving in a dilute acetic acid solution, uniformly mixing, and stirring at room temperature overnight to obtain a polyethylene glycol modified chitosan solution; (4) Dissolving the anthocyanin-carrying nanoparticles obtained in the step (2) in acetic acid aqueous solution, dropwise adding the polyethylene glycol modified chitosan solution obtained in the step (3), stirring at room temperature, centrifuging, and freeze-drying to obtain the anthocyanin-carrying nanoparticles PEG-CS@HPDA@MAS.
Preferably, in the step (1), in the ethanol aqueous solution, the volume ratio of ethanol to water is 1:1.
preferably, the mass fraction of the hydrofluoric acid aqueous solution is 3-5%.
Preferably, in the step (3), the mass ratio of chitosan to polyethylene glycol is 1:0.2 to 0.3.
Preferably, in the step (3), the mass fraction of the dilute acetic acid aqueous solution is 1-2%.
Preferably, in the step (4), the mass fraction of the acetic acid aqueous solution is 0.5-1%.
Preferably, in the step (4), the freeze-drying temperature is-40 to-70 ℃ and the freeze-drying time is 12-24 hours.
The beneficial effects are that: compared with the prior art, the invention has the following beneficial effects:
(1) According to the invention, polydopamine is taken as a base material, and through synthesis of hollow mesoporous polydopamine nanoparticles, loading of anthocyanin and coating of modified chitosan molecules, the drug-loaded hollow mesoporous polydopamine nanoparticles which can improve stability of anthocyanin and take modified chitosan as a coating are constructed, and as the outer chitosan also has antioxidant and anticancer effects, anthocyanin exposure to air can be avoided, so that the anthocyanin-loaded nanoparticles can maintain higher DPPH, hydroxyl radical scavenging activity and anticancer activity of anthocyanin, and stability of anthocyanin is improved.
(2) The carrier hollow Mesoporous Polydopamine (MPDA) has higher specific surface area, nano pore canal structure and internal hollow structure than mesoporous polydopamine, has strong adsorption capacity, and can greatly improve the loading efficiency of the mulberry anthocyanin through ionic bonding and pi-pi accumulation between the anthocyanin so as to solve the problem that the anthocyanin is easy to oxidize and needs a large amount of administration.
(3) The modified chitosan can be absorbed and utilized by human body, has good biocompatibility, can be biodegraded, and the chitosan oligosaccharide produced in the degradation process is not accumulated in the body, has almost no immunogenicity, has good water solubility, changes the electrical property of the surface of the hollow mesoporous polydopamine nano-carrier into positive electricity through chitosan modification, and increases the adhesiveness of the hollow mesoporous polydopamine carrier to tumor cells. The chitosan can be adsorbed in intestinal tracts and is delayed to be discharged out of the body, so that the anthocyanin absorbed by the human body is more, the bioavailability is improved, and the particle storage stability can be improved by wrapping the chitosan on the surface.
(4) The mesoporous polydopamine-loaded mulberry anthocyanin nanoparticles disclosed by the invention have the advantages that the external chitosan and the polydopamine layer can be slowly degraded in intestinal juice, the erosion of gastric acid on the nanoparticles can be delayed in the stomach digestion process, the nanoparticles can be slowly released in small intestinal juice, and the transmission process of anthocyanin in the gastrointestinal tract can be controlled.
(5) The hollow mesoporous polydopamine carrier constructed by the invention is safe, nontoxic, simple in preparation, single in component, capable of improving stability of anthocyanin and convenient to store.
Drawings
FIG. 1 is a graph showing a particle size distribution diagram of hollow mesoporous polydopamine carrier and hollow mesoporous polydopamine-carried mulberry anthocyanin nanoparticles;
fig. 2 is a transmission electron microscope image of the hollow mesoporous polydopamine carrier and the hollow mesoporous polydopamine-carried mulberry anthocyanin nanoparticles;
FIG. 3 is a graph of nitrogen adsorption/desorption for hollow mesoporous polydopamine HPDA;
fig. 4 biosafety inspection of normal human hepatocytes LO2 with blank vector;
fig. 5 is a slow release graph of hollow mesoporous polydopamine-loaded mulberry anthocyanin nanoparticles in simulated gastric fluid and intestinal fluid.
Fig. 6 is a study of oxidation resistance of hollow mesoporous polydopamine-loaded mulberry anthocyanin nanoparticles;
fig. 7 is a study of stability of hollow mesoporous polydopamine-loaded mulberry anthocyanin nanoparticles;
FIG. 8 cytotoxicity of hollow mesoporous polydopamine nanoparticles against human lung cancer cell A549.
Detailed Description
The present invention will be described in detail with reference to the accompanying drawings.
Embodiment 1:
the embodiment provides a preparation method of hollow mesoporous polydopamine mulberry anthocyanin nanoparticle PEG-CS@HPDA@MAS, which is implemented by the following steps:
Adding 0.3 g dopamine hydrochloride and 0.8 g Pluronic F127 into a mixed solution of ethanol water (1:1, v/v), stirring at room temperature, adding 20 mg silica particles after stirring uniformly, and then dropwise adding 0.8 mL TMB to form a white emulsion; adding 4.0 mL ammonia water solution, stirring for 30 min at 50 ℃, centrifuging, ultrasonically washing the precipitate with ethanol and water for 3 times, adding the precipitate into 4% hydrofluoric acid water solution for etching, centrifuging, washing with deionized water for several times to obtain hollow mesoporous polydopamine nanoparticles, and marking as HPDA.
The hollow mesoporous polydopamine nanoparticle and mulberry anthocyanin powder are mixed according to the mass ratio of 7:1 is added into deionized water, stirred at room temperature for reaction 24 h, centrifuged, and washed with deionized water for 3 times to obtain mulberry anthocyanin-carrying nanoparticles, and the mulberry anthocyanin-carrying nanoparticles are marked as HPDA@MAS;
Weighing 1 g chitosan and 0.25 g polyethylene glycol, dissolving in 1.5% dilute acetic acid solution, mixing uniformly, and stirring overnight at room temperature to obtain polyethylene glycol modified chitosan solution; dissolving mulberry anthocyanin-carrying nanoparticles in 100 mL of 0.5% acetic acid water, dropwise adding 20 mL polyethylene glycol modified chitosan solution, stirring at room temperature, centrifuging, and freeze-drying at-70 ℃ to 12 h to obtain hollow mesoporous polydopamine mulberry anthocyanin-carrying nanoparticles PEG-CS@HPDA@MAS.
The prepared hollow mesoporous polydopamine mulberry anthocyanin nanoparticle PEG-CS@HPDA@MAS comprises the following components in percentage by mass: 9:8, hollow mesoporous polydopamine nanoparticles, mulberry anthocyanin and polyethylene glycol modified chitosan are used as carriers, and the polyethylene glycol modified chitosan is wrapped on the outermost layer through physical and chemical adsorption of the mulberry anthocyanin.
Embodiment 2:
the preparation method of the mesoporous polydopamine-carried mulberry anthocyanin nanoparticle is implemented according to the following steps:
Adding 0.4 g dopamine hydrochloride and 1.0 g Pluronic F127 into a mixed solution of ethanol water (1:1, v/v), stirring at room temperature, adding 25 mg silicon dioxide particles after stirring uniformly, then dropwise adding 1.0 mL TMB to form white emulsion, adding 4.5 mL ammonia water solution, stirring at 50 ℃ for 40 min, centrifuging, ultrasonically washing the precipitate with ethanol and water for 5 times, adding the precipitate into a 3% hydrofluoric acid aqueous solution for etching, centrifuging, washing with deionized water for several times to obtain hollow mesoporous polydopamine nanoparticles, and marking as HPDA.
The hollow mesoporous polydopamine nanoparticle and mulberry anthocyanin powder are mixed according to the mass ratio of 8:1 is added into deionized water, stirred at room temperature for reaction 12 h, centrifuged, and washed with deionized water for 5 times to obtain mulberry anthocyanin-carrying nanoparticles, and the mulberry anthocyanin-carrying nanoparticles are marked as HPDA@MAS;
Weighing 1 g chitosan and 0.3 g polyethylene glycol, dissolving in 2% dilute acetic acid solution, mixing uniformly, and stirring overnight at room temperature to obtain polyethylene glycol modified chitosan solution; dissolving mulberry anthocyanin-carrying nanoparticles in 100 mL of 1% acetic acid water, dropwise adding 20 mL polyethylene glycol modified chitosan solution, stirring at room temperature, centrifuging, and freeze-drying at-40 ℃ for 24 h to obtain hollow mesoporous polydopamine mulberry anthocyanin-carrying nanoparticles PEG-CS@HPDA@MAS.
The prepared hollow mesoporous polydopamine mulberry anthocyanin nanoparticle PEG-CS@HPDA@MAS comprises the following components in percentage by mass: 8:7, taking the hollow mesoporous polydopamine nanoparticle, mulberry anthocyanin and polyethylene glycol modified chitosan as a carrier, and wrapping the polyethylene glycol modified chitosan on the outermost layer through physical and chemical adsorption of the mulberry anthocyanin.
Embodiment 3:
the preparation method of the hollow mesoporous polydopamine-carried mulberry anthocyanin nanoparticle is implemented according to the following steps:
Adding 0.5 g dopamine hydrochloride and 1.2 g Pluronic F127 into a mixed solution of ethanol water (1:1, v/v), stirring at room temperature, adding 30 mg silicon dioxide particles after stirring uniformly, then dropwise adding 1.0 mL TMB to form white emulsion, adding 5.0 mL ammonia water solution, stirring at 40 ℃ for 30 min, centrifuging, ultrasonically washing the precipitate with ethanol and water for 5 times, adding the precipitate into a 5% hydrofluoric acid aqueous solution for etching, centrifuging, washing with deionized water for several times to obtain hollow mesoporous polydopamine nanoparticles, and marking as HPDA.
Adding mesoporous polydopamine nanoparticles and mulberry anthocyanin powder into deionized water according to the mass ratio of 10:1, stirring at room temperature to react for 24 h, centrifuging, and washing with deionized water for 5 times to obtain mulberry anthocyanin-carrying nanoparticles, wherein the mulberry anthocyanin-carrying nanoparticles are marked as HPDA@MAS;
Weighing 1 g chitosan and 0.25 g polyethylene glycol, dissolving in 2% dilute acetic acid solution, mixing uniformly, and stirring overnight at room temperature to obtain polyethylene glycol modified chitosan solution; dissolving mulberry anthocyanin-carrying nanoparticles in 100 mL of 0.5% acetic acid water, dropwise adding 20 mL polyethylene glycol modified chitosan solution, stirring at room temperature, centrifuging, and freeze-drying at-40 ℃ for 24 h to obtain hollow mesoporous polydopamine mulberry anthocyanin-carrying nanoparticles PEG-CS@HPDA@MAS.
The prepared hollow mesoporous polydopamine mulberry anthocyanin nanoparticle PEG-CS@HPDA@MAS comprises the following components in percentage by mass: 10:9, hollow mesoporous polydopamine nanoparticles, mulberry anthocyanin and polyethylene glycol modified chitosan are used as carriers, and the polyethylene glycol modified chitosan is wrapped on the outermost layer through physical and chemical adsorption of the mulberry anthocyanin.
And analyzing the particle size distribution of the hollow mesoporous polydopamine carrier and the hollow mesoporous polydopamine-carried mulberry anthocyanin nanoparticles by adopting a Markov laser particle sizer. The hollow mesoporous polydopamine carrier and the hollow mesoporous polydopamine-carried mulberry anthocyanin nanoparticles are dispersed in water, and the particle size distribution is measured, and as shown in figure 1, the hydrodynamic diameters of the hollow mesoporous polydopamine carrier and the hollow mesoporous polydopamine-carried mulberry anthocyanin nanoparticles are 138+/-10 nm and 142+/-10 nm respectively.
Observing the morphology of the hollow mesoporous polydopamine carrier and the hollow mesoporous polydopamine-carried mulberry anthocyanin nanoparticle by a Transmission Electron Microscope (TEM): and (3) taking 10 mu L of the solution, dripping the solution on the surface carbon-coated copper mesh, and naturally air-drying at room temperature. And under the condition of 200KV voltage, observing the morphology, the particle size and the dispersion condition of the nano particles by a transmission electron microscope. The carrier transmission electron microscope picture is shown in figure 2a, the prepared HPDA has a narrow particle size distribution range, uniform particle size and obvious pore channel structure on the surface. The hollow mesoporous polydopamine-carried mulberry anthocyanin nanoparticles are shown in fig. 2b, and the nanoparticles are uniform in particle size and spherical in shape, and regularly distributed pore channels become fuzzy due to adsorption of surface mulberry anthocyanin and modification of chitosan.
HPDA nitrogen adsorption/desorption curve determination: taking dried 80 mg HPDA sample, measuring nitrogen adsorption/desorption curve by instrument, and calculating specific surface area of prepared HPDA nanoparticle as 52.6973 m per gram by BJH method as shown in figure 3.
The growth inhibition effect of the blank vector on human normal hepatocytes LO2 was examined by MTT method. The normal human liver cell LO2 is used, 200 mu L/hole of blank carrier solution with different concentrations is added into an experimental group, 200 mu L of culture solution is added into a control group, and the relative cell viability is taken as an investigation index under two pH conditions to investigate the cell viability of the normal human liver cell LO2 under different concentration conditions. As shown in FIG. 4, when the concentration of the empty nanoparticle reaches 1000 mug/mL, the survival rate of the human normal liver cell LO2 is over 80%, which indicates that the carrier material has good biocompatibility within the concentration of 0.98-1000 mug/mL.
And (3) examining the release condition of the hollow mesoporous polydopamine anthocyanin-carrying nanoparticles in simulated gastric juice and simulated intestinal juice by adopting a dialysis bag method. Placing the hollow mesoporous polydopamine anthocyanin-carrying nanoparticle suspension of 1 mL in a dialysis bag, shaking at constant temperature at 37 ℃ with release medium being simulated artificial gastric juice and artificial intestinal juice, sampling at different time points, and drawing an accumulated drug release curve. The experimental result is shown in fig. 5, and it can be seen from the graph that the release rate of the hollow mesoporous polydopamine anthocyanin-carrying nanoparticle in simulated gastric fluid is higher than that in simulated intestinal fluid, the cumulative release rate is more than 80%, and the release is complete. The hollow mesoporous polydopamine anthocyanin-carrying nanoparticle slowly releases from the beginning of an experiment and is gradually stable along with the time, which proves that the hollow mesoporous polydopamine anthocyanin-carrying nanoparticle has obvious effect in the aspect of anthocyanin controlled release.
And (3) measuring the oxidation resistance of the mulberry anthocyanin by adopting a DPPH method. Respectively sucking the 2 mL hollow mesoporous polydopamine-loaded mulberry anthocyanin nanoparticle suspension and a 2 mLDPPH solution test tube, mixing and shaking uniformly, standing for 30 min in a dark environment, measuring the absorbance, and taking Vc solution as a positive control. The results are shown in FIG. 6. With the gradual increase of the concentration of the samples, the scavenging capacity of each sample on DPPH free radical is gradually enhanced, when the addition amount is within the concentration range of 5-20 mug/mL, the increasing trend of the scavenging rate is slowed down, and when the concentration reaches a certain level, the scavenging rate is not increased but is stabilized. And the clearance rate of the anthocyanin-carrying nanoparticles and the free anthocyanin is higher than that of the positive control Vc in the test concentration range. Therefore, the anthocyanin-carrying nanoparticle has stronger DPPH free radical elimination activity.
Thermal stability study: and (3) placing a certain amount of hollow mesoporous polydopamine-loaded mulberry anthocyanin nanoparticle suspension in a water bath at 50 ℃ and in a dark condition for experiment, and respectively measuring the content of the hollow mesoporous polydopamine-loaded mulberry anthocyanin nanoparticle suspension and the unloaded mulberry anthocyanin solution by an ultraviolet spectrophotometer method on the 0 th day, the 1 st day, the 2 nd day, the 3 rd day, the 4 th day and the 5 th day respectively. As shown in fig. 7, the residual rate of the hollow mesoporous polydopamine-loaded mulberry anthocyanin is higher than that of the non-loaded mulberry anthocyanin.
The toxic effects of free mulberry anthocyanin and PEG-CS@HPDA@MAS on human lung cancer cells A549 cancer cells are examined through an MTT test. The results are shown in fig. 8, and the mulberry anthocyanin shows obvious dose-dependent inhibition effect on human lung cancer cell a549 under two pH conditions. This enhanced antitumor effect of the mulberry anthocyanin after being supported on the carrier may be due to the excellent antiproliferative activity of the chelated mulberry anthocyanin and the synergistic antitumor effect of the mulberry anthocyanin and the surface-modified chitosan coating.
The foregoing embodiments are merely illustrative of the technical concept and features of the present invention, and are intended to enable those skilled in the art to understand the present invention and to implement the same, not to limit the scope of the present invention. All equivalent changes or modifications made according to the spirit of the present invention should be included in the scope of the present invention.
Claims (9)
1. The preparation method of the anthocyanin-carrying nanoparticle is characterized by comprising the following steps:
(1) Adding dopamine hydrochloride and Pluronic F127 into an ethanol aqueous solution, stirring at room temperature uniformly, adding silicon dioxide particles, then dropwise adding TMB to form white emulsion, adding an ammonia aqueous solution, stirring, centrifuging, ultrasonically washing the precipitate with ethanol and water for a plurality of times, adding the precipitate into a hydrofluoric acid aqueous solution for etching, centrifuging to obtain hollow mesoporous polydopamine nanoparticles, and marking as HPDA;
the weight-volume ratio of the dopamine hydrochloride to the Pluronic F127 to the silicon dioxide to the TMB to the ammonia solution is 0.2-0.5 g: 0.8-1.2 g: 0.8-1.0 mL: 4.0-5.0 mL;
(2) Adding the hollow mesoporous polydopamine nanoparticle obtained in the step (1) and anthocyanin powder into deionized water, stirring at room temperature for reaction, centrifuging, and washing with deionized water for several times to obtain anthocyanin-carrying nanoparticle, wherein the anthocyanin-carrying nanoparticle is marked as HPDA@MAS;
the mass ratio of the hollow mesoporous polydopamine nanoparticle to the anthocyanin powder is 7-11: 1, a step of;
(3) Weighing a certain amount of chitosan and polyethylene glycol, dissolving in a dilute acetic acid solution, uniformly mixing, and stirring at room temperature overnight to obtain a polyethylene glycol modified chitosan solution;
(4) Dissolving the anthocyanin-carrying nanoparticles obtained in the step (2) in acetic acid aqueous solution, dropwise adding the polyethylene glycol modified chitosan solution obtained in the step (3), stirring at room temperature, centrifuging, and freeze-drying to obtain the anthocyanin-carrying nanoparticles PEG-CS@HPDA@MAS;
the anthocyanin-carrying nanoparticle PEG-CS@HPDA@MAS comprises the following components in percentage by mass of 52-59: 8-11: 6-10 hollow mesoporous polydopamine nanoparticles, anthocyanin and polyethylene glycol modified chitosan.
2. The method of preparing anthocyanin-loaded nanoparticles according to claim 1, wherein in step (1), the volume ratio of ethanol to water in the aqueous ethanol solution is 1:1.
3. the method for preparing anthocyanin-carrying nanoparticles according to claim 1, wherein in the step (1), the mass fraction of the hydrofluoric acid aqueous solution is 3-5%.
4. The method for preparing anthocyanin-loaded nanoparticles according to claim 1, wherein in the step (3), the mass ratio of chitosan to polyethylene glycol is 1:0.2-0.3.
5. The method of claim 4, wherein in the step (3), the mass fraction of the dilute acetic acid aqueous solution is 1-2%.
6. The method for preparing anthocyanin-supported nanoparticles according to claim 1, wherein in the step (4), the mass fraction of the aqueous acetic acid solution is 0.5-1%.
7. The method for preparing anthocyanin-supported nanoparticles according to any one of claims 1 to 6, wherein in the step (4), the freeze-drying temperature is-40 to-70 ℃ and the freeze-drying time is 12 to 24 hours.
8. The method for preparing anthocyanin-carrying nanoparticles according to any one of claims 1 to 6, wherein the hollow mesoporous polydopamine nanoparticles are used as carriers in the prepared anthocyanin-carrying nanoparticles PEG-CS@HPDA@MAS, the anthocyanin is adsorbed by physical and chemical adsorption, and the polyethylene glycol modified chitosan is coated on the outermost layer.
9. The method for preparing anthocyanin-carrying nanoparticles according to any one of claims 1 to 6, wherein the anthocyanin is mulberry anthocyanin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210025792.2A CN114392248B (en) | 2020-12-31 | 2020-12-31 | Preparation method of anthocyanin-carrying nanoparticles |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011631110.XA CN112516114B (en) | 2020-12-31 | 2020-12-31 | Anthocyanin-loaded nanoparticle |
| CN202210025792.2A CN114392248B (en) | 2020-12-31 | 2020-12-31 | Preparation method of anthocyanin-carrying nanoparticles |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011631110.XA Division CN112516114B (en) | 2020-12-31 | 2020-12-31 | Anthocyanin-loaded nanoparticle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114392248A CN114392248A (en) | 2022-04-26 |
| CN114392248B true CN114392248B (en) | 2023-06-30 |
Family
ID=74977131
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011631110.XA Active CN112516114B (en) | 2020-12-31 | 2020-12-31 | Anthocyanin-loaded nanoparticle |
| CN202210025792.2A Active CN114392248B (en) | 2020-12-31 | 2020-12-31 | Preparation method of anthocyanin-carrying nanoparticles |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011631110.XA Active CN112516114B (en) | 2020-12-31 | 2020-12-31 | Anthocyanin-loaded nanoparticle |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112516114B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114773634A (en) * | 2022-03-22 | 2022-07-22 | 上海大学 | Ultra-small poly-dopamine nano particle and preparation method and application thereof |
| CN115119933A (en) * | 2022-05-06 | 2022-09-30 | 广州大丘有机农产有限公司 | Pitaya enzyme and fermentation preparation process thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150085144A (en) * | 2014-01-13 | 2015-07-23 | 한국과학기술원 | Fabrication method of polydopamine nano-particle and the polydopamine nano-particle thereby |
| CN110693851A (en) * | 2019-10-24 | 2020-01-17 | 西安医学院 | Mesoporous silica drug-loaded nanoparticle and preparation method and application thereof |
| CN112022837A (en) * | 2020-09-14 | 2020-12-04 | 安徽理工大学 | Nano delivery system and preparation method and application thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101219144B (en) * | 2007-01-12 | 2010-10-13 | 上海医药工业研究院 | Long-circulation nano-grain of hydroxycamptothecin and method for preparing the same |
| CN102319217B (en) * | 2011-07-26 | 2013-09-18 | 浙江大学医学院附属妇产科医院 | Polysaccharide coated magnetic nano-particle and preparation method |
| KR101587984B1 (en) * | 2013-07-01 | 2016-01-28 | 주식회사 엘지화학 | Surface-treated article and method for the same |
| CN106511300B (en) * | 2016-10-21 | 2019-06-18 | 青岛农业大学 | Albumen-procyanidine composite nanometer particle and preparation method thereof |
| CN106806343B (en) * | 2017-02-17 | 2020-10-13 | 清华大学深圳研究生院 | Folic acid and polydopamine modified tumor targeting mesoporous silica nanoparticle and preparation method and application thereof |
| CN106806344B (en) * | 2017-02-17 | 2020-10-30 | 清华大学深圳研究生院 | Polydopamine and polyethylene glycol vitamin E succinate modified mesoporous silica nanoparticle and preparation method and application thereof |
| CN107312205B (en) * | 2017-06-15 | 2020-02-11 | 淮阴工学院 | Preparation and application of attapulgite-loaded chitosan cross-linked cyclodextrin compound |
| CN107474160B (en) * | 2017-08-10 | 2019-05-28 | 山东师范大学 | A kind of Phosphorylcholine base polyethylene glycol-chitosan and preparation method thereof |
| CN108837161B (en) * | 2018-08-24 | 2021-05-11 | 东华大学 | Polydopamine-coated gold core/hollow silicon shell nano material and preparation and application thereof |
| CN109276721B (en) * | 2018-09-19 | 2022-02-01 | 中山大学 | Targeting mesoporous polydopamine multifunctional nano diagnosis and treatment agent and preparation method and application thereof |
| CN109528690B (en) * | 2018-12-28 | 2020-10-16 | 陕西师范大学 | Double-response hollow mesoporous silicon-coated polydopamine grafted polyethylene glycol methacrylate drug-loaded microsphere and preparation method thereof |
| CN110204711B (en) * | 2019-05-31 | 2021-11-30 | 中国药科大学 | Preparation method and application of pomegranate-like structure hollow mesoporous molecularly imprinted polydopamine nanoparticle adsorbent |
| CN110522734B (en) * | 2019-08-30 | 2021-04-16 | 大连理工大学 | Preparation method of composite nano-microspheres with polydopamine as template |
| CN111110652B (en) * | 2020-01-06 | 2022-03-29 | 重庆医科大学 | Drug-loaded hyaluronic acid polydopamine-coated mesoporous polydopamine nanoparticle and preparation method thereof |
-
2020
- 2020-12-31 CN CN202011631110.XA patent/CN112516114B/en active Active
- 2020-12-31 CN CN202210025792.2A patent/CN114392248B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150085144A (en) * | 2014-01-13 | 2015-07-23 | 한국과학기술원 | Fabrication method of polydopamine nano-particle and the polydopamine nano-particle thereby |
| CN110693851A (en) * | 2019-10-24 | 2020-01-17 | 西安医学院 | Mesoporous silica drug-loaded nanoparticle and preparation method and application thereof |
| CN112022837A (en) * | 2020-09-14 | 2020-12-04 | 安徽理工大学 | Nano delivery system and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| Redox-Sensitive Nanoscale Coordination Polymers for Drug Delivery and Cancer Theranostics;Zhao et al.;《ACS Appl Mater Interfaces》;第9卷(第28期);23555-23563 * |
| 介孔聚多巴胺纳米核壳结构粒子的制备及吸附性能研究;陈天弟;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;B014-310 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114392248A (en) | 2022-04-26 |
| CN112516114B (en) | 2022-03-22 |
| CN112516114A (en) | 2021-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114452268B (en) | Preparation method of mesoporous polydopamine anthocyanin-carrying nanoparticle | |
| CN115192543B (en) | Preparation method of lipid-loaded soluble pigment nanoparticles | |
| CN114392248B (en) | Preparation method of anthocyanin-carrying nanoparticles | |
| CN111671914B (en) | Near infrared light response nanoparticle and controlled release system | |
| Patiño-Herrera et al. | Prolonged release of metformin by SiO2 nanoparticles pellets for type II diabetes control | |
| CN110302175B (en) | Lipoic acid nanocapsule containing hydrophobic cavity and preparation method and application thereof | |
| Yu et al. | The evaluation of proanthocyanidins/chitosan/lecithin microspheres as sustained drug delivery system | |
| Braga | Cyclodextrin superstructures for drug delivery | |
| Wang et al. | Fabrication of BSA-Pinus koraiensis polyphenol-chitosan nanoparticles and their release characteristics under in vitro simulated gastrointestinal digestion | |
| CN115040496B (en) | Preparation method of hollow mesoporous polydopamine lipid-loaded soluble pigment nanoparticles | |
| CN114010799A (en) | Photo-thermal synergistic chemotherapy targeted degradable nano-drug carrier and preparation method thereof | |
| CN109512785A (en) | A kind of preparation method of folic acid-Pluronic F87 modification curcumin nano-lipid body | |
| CN101696278B (en) | Preparation method of Trolox- chitosan self-assembly nano-particles | |
| CN113633786B (en) | Bovine serum albumin-hydrophobic modified chitosan nano microcapsule and preparation method thereof | |
| Bao et al. | Taste masking of a drug by pH-responsive coordination polymer-coated mesoporous silica nanoparticles | |
| CN113244234B (en) | Aureoamidol ester-barbaloin-palmitate self-assembled nanoparticles and preparation method and application thereof | |
| Noreen et al. | Polymeric complex nanocarriers of Mangifera indica gum & chitosan for methotrexate delivery: Formulation, characterization, and in vitro toxicological assessment | |
| CN114522150A (en) | Preparation method and application of pH-sensitive plant microcapsule nano extruder | |
| CN110200980B (en) | Oral nanoparticles of artemisinin-loaded citrus pectin | |
| CN111773200A (en) | Surface coating degradable in acidic environment and preparation method and application thereof | |
| CN110693849A (en) | Preparation method of fluorouracil targeted sustained-release medicament based on ganoderma lucidum spores | |
| Li et al. | Fabrication and characterization of shellac nanofibers with colon-targeted delivery of quercetin and its anticancer activity | |
| CN107501440A (en) | A kind of new carboxymethyl chitosan derivative and its preparation method and application | |
| CN114948910A (en) | Chinese chestnut shell polyphenol sustained-release material with small intestine targeted release, and preparation and application thereof | |
| CN116327737B (en) | Preparation method of resveratrol microcapsule based on metal-organic framework |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20220426 Assignee: Zibo Hefeng Seed Technology Co.,Ltd. Assignor: HUAIYIN INSTITUTE OF TECHNOLOGY Contract record no.: X2023990000959 Denomination of invention: Preparation method of anthocyanin loaded nanoparticles Granted publication date: 20230630 License type: Common License Record date: 20231205 |